Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of de novo myelodysplastic syndrome (MDS) OR de novo myelodysplastic/myeloproliferative neoplasias (MDS/MPN) including MDS/MPN-RS-T, MDS/MPNu, aCML or CMML~2. Very low/low/intermediate risk disease: IPSS-R up to 3.5 for MDS; MDS/MPN \< 10% bone marrow blasts; for CMML low or intermediate risk according to CPSS-Score~3. Symptomatic anemia (based on valid and complete hemoglobin and transfusion history):~   * NTD (non transfusion dependent): \< 3 RBC transfusions and mean hemoglobin level \<10 g/dl within the last 16 weeks~  * LTB (low transfusion burden): 3-7 RBC transfusions within the last 16 weeks in at least two transfusion episodes, maximum 3 in 8 weeks~  * HTB (high transfusion burden): ≥ 8 RBC transfusions within the last 16 weeks, ≥ 4 in 8 weeks~4. Defined transfusion strategy~5. No available option of an approved MDS therapy and classification of prior erythropoiesis-stimulating agent (ESA) treatment as follows:~   * Cohort A: ESA exposed (and refractory or intolerant)~  * Cohort B: ESA naive AND serum erythropoietin level \>200 U/L~Exclusion Criteria:~Compliance with major study procedures~* Inability to swallow and retain oral medications (\> 10 pills)~* Patient does not accept bone marrow sampling during screening and after the treatment~* Patient does not accept up to weekly peripheral blood sampling during screening and treatment~Safety~* ECOG performance status ≥ 3~* Inacceptable organ function~  1. Serum creatinine \> 2 × ULN or calculated creatinine clearance \< 30 ml/min~ 2. AST \> 2 × ULN or ALT \> 2 × ULN~ 3. total bilirubin \> 2 × ULN (exception \>3 × ULN in patients with documented Gilbert's syndrome)~Interfering treatments~* Prior treatment with azacitidine or decitabine~* Treatment with erythropoiesis stimulating agent (ESA), G-CSF, GM-CSF, lenalidomide, luspatercept and/or another investigational drug or device up to 14 days before registration~* Treatment with iron chelation therapy 56 days before registration, except for subjects on a stable or decreasing dose for at least eight weeks prior to inclusion and during study treatment~* Major surgery within 28 days prior to registration~Concomitant diseases~* Known human immunodeficiency virus infection (HIV)~* Active infectious hepatitis (HBV or HCV)~* Hepatitis virus detectable within 6 months before registration in patients with a history of hepatitis~* History of other invasive malignancy, unless definitively treated with curative intent, provided it is deemed to be at low risk for recurrence by the treating physician~* Presence of an acute or chronic toxicity resulting from prior anti-cancer therapy that has not resolved to Grade ≤ 1 (except anemia and alopecia)~* Known allergy or hypersensitivity to any component of the formulation of CA-494824~* Severe cardiovascular disease (e.g. myocardial infarction within 6 months registration, unstable angina within 6 months registration, NYHA Class III or greater congestive heart failure, serious arrhythmias uncontrolled on treatment, clinically significant pericardial disease, known QTc abnormality \> 450 msec on ECG~Formal requirements~* Positive serum pregnancy test in women of childbearing potential~* Women of childbearing potential and men who partner with a woman of childbearing potential unwilling to use highly effective contraceptive methods for the duration of the study and for 90 days after the last dose of CA-4948~* Age under 18 years at registration~* Inability to provide written informed consent~* Simultaneous participation in another interventional clinical trial or participation in any clinical trial involving administration of an investigational medicinal product within 28 days prior registration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CA-4948 treatment (Type: OTHER): Single-arm design. all patients are treated with IMP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility